[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Kim ES, Kim KJ, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK: Metaplastic ossification in a cutaneous pyogenic granuloma: a case report. J Dermatol; 2004 Apr;31(4):326-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic ossification in a cutaneous pyogenic granuloma: a case report.
  • Cutaneous ossification may occur in association with a variety of cutaneous neoplasms and inflammatory conditions, such as pilomatricomas, basal cell carcinomas, nevi, chondroid syringomas, venous stasis, and scars.
  • However, it has rarely been reported in pyogenic granuloma, a relatively common benign vascular tumor of the skin and mucous membranes.
  • We herein presented a rare case of cutaneous pyogenic granuloma with ectopic ossification on the big toe of a 37-year-old man, with high recurrence despite repeated CO2 laser ablations.
  • We propose the hypothesis that vascular endothelial growth factor (VEGF) and bone morphogenetic proteins (BMPs) play pathologic roles in the development of ectopic bone formation in pyogenic granuloma.
  • [MeSH-major] Granuloma, Pyogenic / diagnosis. Neoplasm Recurrence, Local / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Caustics / administration & dosage. Diagnosis, Differential. Drug Administration Schedule. Humans. Laser Therapy. Male. Ossification, Heterotopic / diagnosis. Ossification, Heterotopic / drug therapy. Ossification, Heterotopic / pathology. Ossification, Heterotopic / surgery. Toes. Trichloroacetic Acid / administration & dosage

  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TRICHLOROACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15187328.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Caustics; 5V2JDO056X / Trichloroacetic Acid
  •  go-up   go-down


2. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, Klagsbrun M: Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest; 2004 Nov;114(9):1260-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype.
  • Melanoma is the most lethal skin cancer.
  • Semaphorins have been shown to inhibit neuronal and endothelial cell migration, but the effects of semaphorins on tumor metastasis have not been documented.
  • Rather, the primary tumors resembled benign nevi characterized by large areas of apoptosis, diminished vascularity, inhibition of hyperplasia in overlying epidermal cells, and encapsulated tumor borders delineated by thick layers of fibroblasts and collagen matrix.
  • This phenotype is in stark contrast to highly invasive, vascular mock-transfected tumors.
  • In vitro, tumor cells expressing SEMA3F had a diminished capacity to adhere and migrate on fibronectin.
  • Consistent with semaphorin-mediated chemorepulsion of neurons, tumor cells expressing SEMA3F were chemorepulsive for vascular and lymphatic endothelial cells expressing neuropilin-2 (NRP2), a novel mechanism for a tumor angiogenesis inhibitor.
  • Together these results indicate that SEMA3F is a potent metastasis inhibitor that targets both tumor and stromal cells and raise the possibility of SEMA3F having therapeutic potential.

  • COS Scholar Universe. author profiles.
  • Nature Publishing Group. commentaries/discussion - Highlights from Nature Reviews Cancer .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Jul 24;424(6947):391-7 [12879061.001]
  • [Cites] Melanoma Res. 2003 Aug;13(4):379-87 [12883364.001]
  • [Cites] Mol Cell Neurosci. 2003 Oct;24(2):409-18 [14572462.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):561-5 [14760364.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1008-15 [14871832.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2139-51 [15161648.001]
  • [Cites] J Natl Cancer Inst. 1984 Apr;72(4):913-7 [6584666.001]
  • [Cites] Prostate. 1986;9(3):261-81 [3774632.001]
  • [Cites] Am J Pathol. 1988 Nov;133(2):419-23 [3189515.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 21;81(12):938-44 [2733038.001]
  • [Cites] J Biol Chem. 1997 Dec 12;272(50):31582-8 [9395496.001]
  • [Cites] Cell. 1998 Mar 20;92(6):735-45 [9529250.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1599-604 [9563467.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):203-8 [9627717.001]
  • [Cites] Neuron. 1997 Sep;19(3):547-59 [9331348.001]
  • [Cites] Neuron. 1997 Nov;19(5):995-1005 [9390514.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1566-77 [12085206.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3274-85 [12093729.001]
  • [Cites] Clin Exp Metastasis. 2002;19(7):609-15 [12498390.001]
  • [Cites] Adv Exp Med Biol. 2002;515:33-48 [12613541.001]
  • [Cites] Dev Biol. 2003 Mar 1;255(1):77-98 [12618135.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):83-92 [12659673.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1951-60 [12759251.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Development. 1998 Nov;125(21):4313-23 [9753685.001]
  • [Cites] J Invest Dermatol. 1998 Nov;111(5):864-72 [9804351.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1627-36 [9816342.001]
  • [Cites] Neuron. 1998 Nov;21(5):1079-92 [9856463.001]
  • [Cites] Neuron. 1998 Dec;21(6):1283-90 [9883722.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):872-9 [10029078.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11721-6 [10206987.001]
  • [Cites] Genomics. 1999 May 1;57(3):459-60 [10329017.001]
  • [Cites] J Cell Biol. 1999 Jul 12;146(1):233-42 [10402473.001]
  • [Cites] Cell. 1999 Oct 1;99(1):59-69 [10520994.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):573-83 [12154350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10470-5 [12142468.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):713-8 [12235205.001]
  • [Cites] Development. 2002 Oct;129(20):4797-806 [12361971.001]
  • [Cites] Dev Dyn. 2002 Nov;225(3):351-7 [12412020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2573-8 [10688880.001]
  • [Cites] Mech Dev. 2000 May;93(1-2):95-104 [10781943.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5410-3 [11034081.001]
  • [Cites] FASEB J. 2000 Dec;14(15):2532-9 [11099472.001]
  • [Cites] J Cell Biochem. 2001;81(1):82-92 [11180399.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1024-9 [11158588.001]
  • [Cites] J Clin Pathol. 2001 Mar;54(3):196-200 [11253130.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1392-400 [11562390.001]
  • [Cites] Mech Dev. 2001 Nov;109(1):115-9 [11677062.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13954-9 [11717452.001]
  • [Cites] J Neurosci. 2002 Jan 15;22(2):471-7 [11784792.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):542-6 [11809707.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3657-62 [11891274.001]
  • [Cites] J Cell Biochem. 2002;85(2):357-68 [11948691.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2637-43 [11980661.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] J Urol. 1995 Oct;154(4):1532-8 [7658585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4120-5 [8633026.001]
  • [Cites] Oncogene. 1996 Mar 21;12(6):1289-97 [8649831.001]
  • [Cites] Genomics. 1996 Feb 15;32(1):39-48 [8786119.001]
  • [Cites] Cell. 1997 Aug 22;90(4):739-51 [9288753.001]
  • [Cites] Cell. 1997 Aug 22;90(4):753-62 [9288754.001]
  • (PMID = 15520858.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA45548; United States / NCI NIH HHS / CA / R56 CA037392; United States / NCI NIH HHS / CA / CA37392; United States / NCI NIH HHS / CA / R37 CA037392; United States / NCI NIH HHS / CA / P01 CA045548; United States / NCI NIH HHS / CA / R01 CA037392
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / Neuropilin-2; 0 / SEMA3F protein, human; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC524226
  •  go-up   go-down


3. Onuma K, Sato Y, Ogawara S, Shirasawa N, Kobayashi M, Yoshitake J, Yoshimura T, Iigo M, Fujii J, Okada F: Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells. Am J Pathol; 2009 Nov;175(5):2171-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells.
  • Nanoparticles are prevalent in both commercial and medicinal products; however, the contribution of nanomaterials to carcinogenesis remains unclear.
  • These results indicate that nano-sized TiO(2) has the potential to convert benign tumor cells into malignant ones through the generation of ROS in the target cells.
  • [MeSH-major] Cell Transformation, Neoplastic / drug effects. Fibrosarcoma. Nanoparticles / chemistry. Neoplasm Invasiveness. Titanium / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytokines / genetics. Cytokines / metabolism. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Dinoprostone / metabolism. Female. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Mice. Mice, Inbred C57BL. Particle Size. Reactive Oxygen Species / metabolism. Thymosin / genetics. Thymosin / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Occup Med. 1988 Dec;30(12):937-42 [3230444.001]
  • [Cites] J Toxicol Environ Health. 1990;29(4):417-29 [2325155.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(6):358-64 [2386981.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):635-9 [1419599.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):233-8 [8054271.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5512-20 [8955201.001]
  • [Cites] J Biochem. 1997 Aug;122(2):459-66 [9378727.001]
  • [Cites] Br Med Bull. 1997;53(3):662-8 [9374044.001]
  • [Cites] FEBS Lett. 1997 Nov 24;418(1-2):87-90 [9414101.001]
  • [Cites] Exp Lung Res. 1998 Jan-Feb;24(1):85-100 [9457471.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 1):L81-6 [9458804.001]
  • [Cites] J Appl Toxicol. 1998 Sep-Oct;18(5):307-12 [9804429.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):377-85 [10027302.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 1999 Sep-Oct;12(5):247-56 [10461093.001]
  • [Cites] FASEB J. 2005 Mar;19(3):311-30 [15746175.001]
  • [Cites] Exp Cell Res. 2005 Apr 15;305(1):51-62 [15777787.001]
  • [Cites] J Am Chem Soc. 2005 Mar 30;127(12):4388-96 [15783221.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):823-39 [16002369.001]
  • [Cites] Toxicology. 2005 Sep 15;213(1-2):66-73 [15970370.001]
  • [Cites] Environ Health Perspect. 2005 Nov;113(11):1555-60 [16263511.001]
  • [Cites] Nitric Oxide. 2006 Mar;14(2):122-9 [16125421.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):341-9 [16507455.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):854-62 [16508635.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):295-6 [16598890.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):294-302 [16816381.001]
  • [Cites] FASEB J. 2006 Nov;20(13):2393-5 [17023518.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18882-6 [17135351.001]
  • [Cites] Toxicol Lett. 2007 Jan 10;168(1):58-74 [17141434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2029-30 [17284585.001]
  • [Cites] Water Sci Technol. 2006;54(11-12):327-34 [17302336.001]
  • [Cites] Mutat Res. 2007 Apr 2;628(2):99-106 [17223607.001]
  • [Cites] Biomaterials. 2007 Jul;28(19):2946-58 [17379299.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2364-72 [17893867.001]
  • [Cites] Oncogene. 2008 Nov 27;27(56):7070-82 [18806824.001]
  • [Cites] Tumour Biol. 2000 Jan-Feb;21(1):11-20 [10601837.001]
  • [Cites] Toxicology. 2001 Aug 28;165(2-3):133-44 [11522371.001]
  • [Cites] Photochem Photobiol. 2001 Nov;74(5):656-69 [11723793.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):869-82 [11891186.001]
  • [Cites] Proc Nutr Soc. 2002 Feb;61(1):123-30 [12002786.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 7):5-11 [12068382.001]
  • [Cites] Biomaterials. 2002 Sep;23(17):3757-64 [12109701.001]
  • [Cites] Toxicol In Vitro. 2002 Oct;16(5):629-35 [12206830.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):455-60 [12676598.001]
  • [Cites] J Biosci. 2003 Feb;28(1):51-5 [12682424.001]
  • [Cites] Pharmacol Ther. 2003 Jul;99(1):113-32 [12804702.001]
  • [Cites] Prog Lipid Res. 2003 Nov;42(6):463-78 [14559067.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2221-32 [14633597.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Feb;286(2):L344-53 [14555462.001]
  • [Cites] Water Sci Technol. 2004;49(1):103-10 [14979544.001]
  • [Cites] Free Radic Biol Med. 2004 Oct 1;37(7):916-25 [15336307.001]
  • [Cites] J Nanosci Nanotechnol. 2004 May;4(5):521-31 [15503438.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 May;72(5):1848-51 [1057174.001]
  • [Cites] Ann N Y Acad Sci. 1976;276:455-65 [1071971.001]
  • [Cites] Int J Cancer. 1987 Mar 15;39(3):338-42 [2434441.001]
  • [Cites] Scand J Work Environ Health. 1987 Feb;13(1):47-51 [3495034.001]
  • (PMID = 19815711.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins; 0 / Reactive Oxygen Species; 0 / Vascular Endothelial Growth Factor A; 15FIX9V2JP / titanium dioxide; 61512-21-8 / Thymosin; 77591-33-4 / thymosin beta(4); 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; D1JT611TNE / Titanium; G9481N71RO / Deoxyguanosine; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2774079
  •  go-up   go-down


Advertisement
4. Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J: Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest; 2001 Mar;107(6):745-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangioma, the most common tumor of infancy, is a benign vascular neoplasm of unknown etiology.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jan;31(1):11-22 [10665907.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):477-89 [10886192.001]
  • [Cites] J Cell Biol. 1990 Feb;110(2):511-7 [2404994.001]
  • [Cites] J Cell Sci. 1990 Jun;96 ( Pt 2):257-62 [2211866.001]
  • [Cites] Genomics. 1992 Feb;12(2):241-53 [1740333.001]
  • [Cites] Am J Hum Genet. 1992 Dec;51(6):1229-39 [1281384.001]
  • [Cites] J Clin Invest. 1993 Feb;91(2):379-87 [7679406.001]
  • [Cites] Blood. 1994 May 15;83(10):2899-905 [8180385.001]
  • [Cites] J Urol. 1995 May;153(5):1697-700 [7715013.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1181-91 [8644859.001]
  • [Cites] Am J Pathol. 1997 Apr;150(4):1315-26 [9094988.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2153-66 [9176406.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):697-705 [9284818.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):927-34 [9486960.001]
  • [Cites] Am J Pathol. 1998 Apr;152(4):913-23 [9546352.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Apr;34(4):308-15 [9590504.001]
  • [Cites] Microcirculation. 1998;5(2-3):189-95 [9789259.001]
  • [Cites] Am J Med Genet. 1999 Jan 1;82(1):77-83 [9916848.001]
  • [Cites] EMBO J. 1999 Aug 16;18(16):4414-23 [10449407.001]
  • [Cites] Am J Hum Genet. 1965 May;17:212-20 [14295491.001]
  • [CommentIn] J Clin Invest. 2001 Mar;107(6):665-6 [11254664.001]
  • (PMID = 11254674.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR036820; United States / NIAMS NIH HHS / AR / AR 36820
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Endostatins; 0 / Peptide Fragments; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC208946
  •  go-up   go-down


5. Zmonarski SC, BoratyƄska M, Puziewicz-Zmonarska A, Kazimierczak K, Klinger M: Kaposi's sarcoma in renal transplant recipients. Ann Transplant; 2005;10(2):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma in renal transplant recipients.
  • Kaposi's sarcoma (KS) is a spindle-shaped vascular cell tumor that occurs in the skin, lymphoid, respiratory and gastrointestinal tissues.
  • It may resemble aggressive malignant neoplasm in HIV-related or in post-transplant types but classic form may behave as benign, potentially controllable and reversible hyperplasia.
  • KS probability increases in solid organ transplant recipients (approximately 3/1000 patients).
  • KS occurrence is associated with: type and dose of immunosuppression, chronic stimulation by foreign allograft antigens, viral infections (Herpes virus 8), anti rejection and induction therapy, etc.
  • Histological picture shows networks of spindle shaped cells and vascular spaces surrounded by an endothelial cell layer.
  • There is no uniform schema of KS treatment in renal transplant recipients.
  • Sirolimus seems to inhibit the growth of established vascularized tumors and this effect is best realized with relatively low immunosuppressive doses of drug.


6. Al-Za'abi AM, Ghazarian D, Greenberg GR, Shaw JC: Eruptive tufted angiomas in a patient with Crohn's disease. J Clin Pathol; 2005 Feb;58(2):214-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angioblastoma is a rare, benign vascular tumour composed of undifferentiated mesenchymal cells with a tendency to form lumina.
  • He developed numerous small itchy erythematous vascular appearing papules, which on histological examination resembled tufted angiomas, showing the classic "cannon ball" appearance.
  • This case may represent an eruptive acquired tufted angioma in which immunosuppression or drug induced modification of angiogenesis played a role in its development and regression.
  • [MeSH-major] Crohn Disease / pathology. Hemangioma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Gastrointestinal Agents / administration & dosage. Humans. Immunocompromised Host. Infliximab. Injections, Intravenous. Male. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatology. 2000;201(1):68-70 [10971067.001]
  • [Cites] Pediatr Dermatol. 1995 Jun;12(2):184-6 [7659649.001]
  • [Cites] Pediatr Dermatol. 2002 Sep-Oct;19(5):388-93 [12383093.001]
  • [Cites] Pediatr Dermatol. 2002 Sep-Oct;19(5):394-401 [12383094.001]
  • [Cites] Arthritis Rheum. 2004 May;50(5):1636-41 [15146434.001]
  • [Cites] N Y State J Med. 1968 Nov 1;68(21):2803-6 [5247013.001]
  • [Cites] Clin Exp Dermatol. 1976 Dec;1(4):287-312 [793743.001]
  • [Cites] Am J Surg Pathol. 1986 Aug;10(8):521-30 [3740350.001]
  • [Cites] J Am Acad Dermatol. 1989 Feb;20(2 Pt 1):214-25 [2644316.001]
  • [Cites] Clin Exp Dermatol. 1991 Mar;16(2):110-3 [2032370.001]
  • [Cites] J Am Acad Dermatol. 1992 Feb;26(2 Pt 2):322-5 [1569251.001]
  • [Cites] Pathol Annu. 1992;27 Pt 2:51-87 [1584628.001]
  • [Cites] J Cutan Pathol. 1994 Oct;21(5):461-6 [7868759.001]
  • [Cites] Clin Exp Dermatol. 1994 Nov;19(6):511-4 [7889677.001]
  • [Cites] Clin Exp Dermatol. 2000 Nov;25(8):627-30 [11167978.001]
  • (PMID = 15677546.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  • [Other-IDs] NLM/ PMC1770572
  •  go-up   go-down


7. Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC: Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol; 2006 Jul;29(1):25-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
  • Tissue factor pathway inhibitor 2 (TFPI-2) is a 32-kDa extracellular matrix-associated kunitz-type serine proteinase inhibitor.
  • It is secreted by all vascular cells and plays a role in tumor invasion and metastasis, presumably by plasmin-mediated matrix remodeling.
  • Previous studies have shown high expression of TFPI-2 by benign tumors and low or absent expression in highly malignant tumors.
  • Restoration of TFPI-2 led to decreased invasiveness of transfected cells compared to parental and vector controls in Matrigel and spheroid assays and inhibition of angiogenesis in in vitro co-cultures with human umbilical vein endothelial cells (HUVEC) and in vivo dorsal skin assay studies.
  • Finally, TFPI-2 overexpression inhibited intracranial tumor formation in nude mice.
  • Our data substantiate our previous observation that TFPI-2 plays an important role in tumor progression and has potential in anti-cancer therapy.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1995 Feb 20;317(1):311-4 [7872799.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] J Biochem. 1994 Nov;116(5):939-42 [7896752.001]
  • [Cites] Arch Biochem Biophys. 1995 May 10;319(1):55-62 [7539605.001]
  • [Cites] Eur J Biochem. 1996 Jan 15;235(1-2):310-6 [8631347.001]
  • [Cites] Cancer. 1996 May 1;77(9):1877-83 [8646688.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):267-8 [8661135.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Trends Biochem Sci. 1997 Aug;22(8):299-306 [9270303.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):40-6 [9445254.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2698-703 [9531578.001]
  • [Cites] Placenta. 1998 Mar-Apr;19(2-3):217-23 [9548189.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):749-56 [9610735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6 [9689032.001]
  • [Cites] Semin Thromb Hemost. 1998;24(3):207-10 [9701449.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4461-7 [9766679.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Cell Death Differ. 1999 Jul;6(7):673-82 [10453078.001]
  • [Cites] Arch Biochem Biophys. 1999 Oct 1;370(1):112-8 [10496984.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Invest Dermatol. 1995 Mar;104(3):379-83 [7861006.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3353-7 [8159751.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):127-31 [11115549.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):570-6 [11297250.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12241-8 [11278667.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):239-44 [11315097.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):591-7 [11494041.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):325-33 [11606093.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6938-45 [11687973.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2184-91 [11929842.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7758-64 [2253219.001]
  • [Cites] J Biochem. 1990 Oct;108(4):537-43 [1963430.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5046-53 [1387587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • (PMID = 16773181.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glycoproteins; 0 / Laminin; 0 / Lipoproteins; 0 / Proteoglycans; 0 / bcl-2-Associated X Protein; 0 / lipoprotein-associated coagulation inhibitor; 0 / tissue-factor-pathway inhibitor 2; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS9141; NLM/ PMC1479607
  •  go-up   go-down






Advertisement